ALDH1A1 (Aldehyde Dehydrogenase 1 family member A1)

Tunçer, Sinem; Çamlica, Rümeysa; Yilmaz, İdris

doi:10.4267/2042/70676

Cited by 2 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aldehyde dehydrogenase 1 family member A1 (ALDH1A1) is the next enzyme after alcohol dehydrogenase in the major pathway of alcohol metabolism (Wu et al, 2020;NCBI, 2021). In addition to alcohol, many drugs can be metabolized by ALDHs, such as EMB, and its L-isomer is metabolized by liver ALDHs to form an aldehyde (oxidative) metabolite.…”

Section: Cytochrome (Cyp) Udp-glucuronosyltransferase (Ugt) Aldehyde ...mentioning

confidence: 99%

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

et al. 2023

View full text Add to dashboard Cite

The World Health Organization (WHO) stated that ensuring access to effective and optimal treatment is a key component to eradicate tuberculosis (TB) through the End TB Strategy. Personalized medicine that depends on the genetic profile of an individual is one way to optimize treatment. It is necessary because of diverse drug responses related to the variation in human DNA, such as single-nucleotide polymorphisms (SNPs). Ethambutol (EMB) is a drug widely used as the treatment for Mycobacterium Tuberculosis (Mtb) and/non-tuberculous mycobacteria and has become a potential supplementary agent for a treatment regimen of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. In human genetic polymorphism studies of anti-tuberculosis, the majority focus on rifampicin or isoniazid, which discuss polymorphisms related to their toxicity. Whereas there are few studies on EMB, the incidence of EMB toxicity is lower than that of other first-line anti-TB drugs. To facilitate personalized medicine practice, this article summarizes the genetic polymorphisms associated with alterations in the pharmacokinetic profile, resistance incidence, and susceptibility to EMB toxicity. This study includes 131 total human studies from 17 articles, but only eight studies that held in the low-middle income country (LMIC), while the rest is research conducted in developed countries with high incomes. Personalized medicine practices are highly recommended to maintain and obtain the optimal therapeutic effect of EMB.

show abstract

Section: Cytochrome (Cyp) Udp-glucuronosyltransferase (Ugt) Aldehyde ...mentioning

confidence: 99%

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It is involved in the metabolism of alcohol. Cytosolic isozyme is encoded by this gene and also plays role in retinol metabolism (Tunçer, Çamlica, and Yilmaz 2020). In the western Chinese Han population, a prospective study including 747 TB patients was conducted who were treated with first-line TB drugs.…”

Section: Cyp7a1mentioning

confidence: 99%

Hepatic Adverse Effects of Anti-Mycobacterium Tuberculosis Drugs and Their Associations with Various Genetic Variants

Javed

Akmal

2022

Precis. Med. Com.

View full text Add to dashboard Cite

Tuberculosis is a significant healthcare burden, especially in the developing world. Current first-line therapies for tuberculosis treatment (isoniazid, pyrazinamide, rifampicin, and ethambutol) have significant efficacy but they all have the potential to cause hepatotoxicity. Effects produced by these drugs may be asymptomatic with increased levels of aminotransferases in some patients or the development of severe hepatotoxicity in others. On the other hand, it can also lead to hepatic failure in some patients. In this review, we evaluated the studies on genetic variants showing associations with drug-induced hepatic injury in tuberculosis patients. Several studies on important genes such as NAT2, AADAC, CYP2E1, HLA, CYP7A1, ALDH1A1, NFkB, PXR, HMOX1, SLCO1B1, UGT1A1, NRF2, and MAFF were reviewed and discussed for utilizing them as predictors of hepatic injury in tuberculosis patients. Recommendations are made on the potential of some of these genetic variants as a screening tool for determining patients most likely to experience hepatic adverse effects after receiving standard first-line anti-mycobacterial tuberculosis treatment.

show abstract

ALDH1A1 (Aldehyde Dehydrogenase 1 family member A1)

Cited by 2 publications

References 36 publications

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

Genetic polymorphism related to ethambutol outcomes and susceptibility to toxicity

Hepatic Adverse Effects of Anti-Mycobacterium Tuberculosis Drugs and Their Associations with Various Genetic Variants

Contact Info

Product

Resources

About